JP5989964B2 - 親水性及び/又は親油性分子をカプセル化するための、水性コア脂質ナノカプセル - Google Patents
親水性及び/又は親油性分子をカプセル化するための、水性コア脂質ナノカプセル Download PDFInfo
- Publication number
- JP5989964B2 JP5989964B2 JP2010525348A JP2010525348A JP5989964B2 JP 5989964 B2 JP5989964 B2 JP 5989964B2 JP 2010525348 A JP2010525348 A JP 2010525348A JP 2010525348 A JP2010525348 A JP 2010525348A JP 5989964 B2 JP5989964 B2 JP 5989964B2
- Authority
- JP
- Japan
- Prior art keywords
- oil
- surfactant
- water
- volatile oil
- aqueous
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 239000002088 nanocapsule Substances 0.000 title claims description 79
- 150000002632 lipids Chemical class 0.000 title claims description 9
- 150000002433 hydrophilic molecules Chemical class 0.000 title description 9
- 150000002634 lipophilic molecules Chemical class 0.000 title description 5
- 239000003921 oil Substances 0.000 claims description 75
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 73
- 238000000034 method Methods 0.000 claims description 65
- 239000000203 mixture Substances 0.000 claims description 62
- 239000004094 surface-active agent Substances 0.000 claims description 61
- 239000012071 phase Substances 0.000 claims description 55
- 239000000178 monomer Substances 0.000 claims description 52
- QWTDNUCVQCZILF-UHFFFAOYSA-N isopentane Chemical compound CCC(C)C QWTDNUCVQCZILF-UHFFFAOYSA-N 0.000 claims description 45
- 239000002245 particle Substances 0.000 claims description 41
- 229920000642 polymer Polymers 0.000 claims description 37
- 238000005538 encapsulation Methods 0.000 claims description 32
- 239000000341 volatile oil Substances 0.000 claims description 32
- 239000000839 emulsion Substances 0.000 claims description 30
- 230000008569 process Effects 0.000 claims description 27
- 239000000346 nonvolatile oil Substances 0.000 claims description 24
- AFABGHUZZDYHJO-UHFFFAOYSA-N dimethyl butane Natural products CCCC(C)C AFABGHUZZDYHJO-UHFFFAOYSA-N 0.000 claims description 22
- 239000000126 substance Substances 0.000 claims description 21
- OGQYPPBGSLZBEG-UHFFFAOYSA-N dimethyl(dioctadecyl)azanium Chemical compound CCCCCCCCCCCCCCCCCC[N+](C)(C)CCCCCCCCCCCCCCCCCC OGQYPPBGSLZBEG-UHFFFAOYSA-N 0.000 claims description 16
- 239000008346 aqueous phase Substances 0.000 claims description 15
- OFBQJSOFQDEBGM-UHFFFAOYSA-N Pentane Chemical compound CCCCC OFBQJSOFQDEBGM-UHFFFAOYSA-N 0.000 claims description 12
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 claims description 10
- DVKJHBMWWAPEIU-UHFFFAOYSA-N toluene 2,4-diisocyanate Chemical group CC1=CC=C(N=C=O)C=C1N=C=O DVKJHBMWWAPEIU-UHFFFAOYSA-N 0.000 claims description 9
- 229920002396 Polyurea Polymers 0.000 claims description 8
- 239000007762 w/o emulsion Substances 0.000 claims description 8
- 239000002086 nanomaterial Substances 0.000 claims description 6
- 239000002736 nonionic surfactant Substances 0.000 claims description 6
- 238000006116 polymerization reaction Methods 0.000 claims description 6
- -1 polyoxyethylene Polymers 0.000 claims description 6
- 239000007787 solid Substances 0.000 claims description 6
- 239000007864 aqueous solution Substances 0.000 claims description 5
- 238000004519 manufacturing process Methods 0.000 claims description 5
- 229920003171 Poly (ethylene oxide) Polymers 0.000 claims description 4
- 239000005662 Paraffin oil Substances 0.000 claims description 3
- 239000011258 core-shell material Substances 0.000 claims description 3
- 239000005058 Isophorone diisocyanate Substances 0.000 claims description 2
- 239000002537 cosmetic Substances 0.000 claims description 2
- 125000005442 diisocyanate group Chemical group 0.000 claims description 2
- NIMLQBUJDJZYEJ-UHFFFAOYSA-N isophorone diisocyanate Chemical compound CC1(C)CC(N=C=O)CC(C)(CN=C=O)C1 NIMLQBUJDJZYEJ-UHFFFAOYSA-N 0.000 claims description 2
- DGTNSSLYPYDJGL-UHFFFAOYSA-N phenyl isocyanate Chemical compound O=C=NC1=CC=CC=C1 DGTNSSLYPYDJGL-UHFFFAOYSA-N 0.000 claims description 2
- 230000000379 polymerizing effect Effects 0.000 claims description 2
- 229920000136 polysorbate Polymers 0.000 claims description 2
- 229950008882 polysorbate Drugs 0.000 claims description 2
- 235000021067 refined food Nutrition 0.000 claims description 2
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 40
- 239000007908 nanoemulsion Substances 0.000 description 36
- 229960004679 doxorubicin Drugs 0.000 description 20
- RBTBFTRPCNLSDE-UHFFFAOYSA-N 3,7-bis(dimethylamino)phenothiazin-5-ium Chemical compound C1=CC(N(C)C)=CC2=[S+]C3=CC(N(C)C)=CC=C3N=C21 RBTBFTRPCNLSDE-UHFFFAOYSA-N 0.000 description 19
- 229960000907 methylthioninium chloride Drugs 0.000 description 19
- 230000000694 effects Effects 0.000 description 13
- 238000002360 preparation method Methods 0.000 description 13
- 239000004530 micro-emulsion Substances 0.000 description 12
- 238000010790 dilution Methods 0.000 description 11
- 239000012895 dilution Substances 0.000 description 11
- 238000009472 formulation Methods 0.000 description 11
- 241000894007 species Species 0.000 description 10
- 238000001704 evaporation Methods 0.000 description 9
- 230000008020 evaporation Effects 0.000 description 9
- 238000006068 polycondensation reaction Methods 0.000 description 9
- 229940079593 drug Drugs 0.000 description 8
- 239000003814 drug Substances 0.000 description 8
- 239000007788 liquid Substances 0.000 description 8
- 238000005259 measurement Methods 0.000 description 8
- 239000002480 mineral oil Substances 0.000 description 8
- 235000010446 mineral oil Nutrition 0.000 description 8
- 230000006641 stabilisation Effects 0.000 description 8
- 238000011105 stabilization Methods 0.000 description 8
- 230000006870 function Effects 0.000 description 7
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 6
- 238000007792 addition Methods 0.000 description 6
- 230000015572 biosynthetic process Effects 0.000 description 6
- 238000009835 boiling Methods 0.000 description 6
- 230000001351 cycling effect Effects 0.000 description 6
- 239000000463 material Substances 0.000 description 6
- 230000002776 aggregation Effects 0.000 description 5
- 238000004220 aggregation Methods 0.000 description 5
- 239000002775 capsule Substances 0.000 description 5
- 238000011002 quantification Methods 0.000 description 5
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 4
- 238000012695 Interfacial polymerization Methods 0.000 description 4
- 229910052799 carbon Inorganic materials 0.000 description 4
- 230000015556 catabolic process Effects 0.000 description 4
- 238000001816 cooling Methods 0.000 description 4
- 238000006731 degradation reaction Methods 0.000 description 4
- 239000006185 dispersion Substances 0.000 description 4
- 238000009826 distribution Methods 0.000 description 4
- 230000007246 mechanism Effects 0.000 description 4
- 239000011148 porous material Substances 0.000 description 4
- 108090000623 proteins and genes Proteins 0.000 description 4
- 102000004169 proteins and genes Human genes 0.000 description 4
- 239000000725 suspension Substances 0.000 description 4
- 229920001059 synthetic polymer Polymers 0.000 description 4
- IAYPIBMASNFSPL-UHFFFAOYSA-N Ethylene oxide Chemical compound C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 description 3
- 238000012696 Interfacial polycondensation Methods 0.000 description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- 238000003917 TEM image Methods 0.000 description 3
- COQLPRJCUIATTQ-UHFFFAOYSA-N Uranyl acetate Chemical compound O.O.O=[U]=O.CC(O)=O.CC(O)=O COQLPRJCUIATTQ-UHFFFAOYSA-N 0.000 description 3
- 230000005540 biological transmission Effects 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 230000007423 decrease Effects 0.000 description 3
- 239000000975 dye Substances 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 238000010438 heat treatment Methods 0.000 description 3
- DKAGJZJALZXOOV-UHFFFAOYSA-N hydrate;hydrochloride Chemical compound O.Cl DKAGJZJALZXOOV-UHFFFAOYSA-N 0.000 description 3
- 238000010348 incorporation Methods 0.000 description 3
- 239000012528 membrane Substances 0.000 description 3
- 239000002953 phosphate buffered saline Substances 0.000 description 3
- 230000002265 prevention Effects 0.000 description 3
- 238000012545 processing Methods 0.000 description 3
- 238000003756 stirring Methods 0.000 description 3
- 239000004907 Macro-emulsion Substances 0.000 description 2
- FHNINJWBTRXEBC-UHFFFAOYSA-N Sudan III Chemical compound OC1=CC=C2C=CC=CC2=C1N=NC(C=C1)=CC=C1N=NC1=CC=CC=C1 FHNINJWBTRXEBC-UHFFFAOYSA-N 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 238000013019 agitation Methods 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 125000003277 amino group Chemical group 0.000 description 2
- 239000002246 antineoplastic agent Substances 0.000 description 2
- 229940041181 antineoplastic drug Drugs 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 239000000084 colloidal system Substances 0.000 description 2
- 230000000295 complement effect Effects 0.000 description 2
- 238000000604 cryogenic transmission electron microscopy Methods 0.000 description 2
- 230000003013 cytotoxicity Effects 0.000 description 2
- 231100000135 cytotoxicity Toxicity 0.000 description 2
- 235000014113 dietary fatty acids Nutrition 0.000 description 2
- 238000007865 diluting Methods 0.000 description 2
- 238000004945 emulsification Methods 0.000 description 2
- 239000000194 fatty acid Substances 0.000 description 2
- 229930195729 fatty acid Natural products 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 238000007429 general method Methods 0.000 description 2
- 150000004676 glycans Chemical class 0.000 description 2
- 238000000265 homogenisation Methods 0.000 description 2
- 238000011065 in-situ storage Methods 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 239000012948 isocyanate Substances 0.000 description 2
- IQPQWNKOIGAROB-UHFFFAOYSA-N isocyanate group Chemical group [N-]=C=O IQPQWNKOIGAROB-UHFFFAOYSA-N 0.000 description 2
- 150000002513 isocyanates Chemical class 0.000 description 2
- 239000011159 matrix material Substances 0.000 description 2
- 239000002105 nanoparticle Substances 0.000 description 2
- 239000002077 nanosphere Substances 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- 239000002773 nucleotide Substances 0.000 description 2
- 125000003729 nucleotide group Chemical group 0.000 description 2
- 239000003208 petroleum Substances 0.000 description 2
- 229920006254 polymer film Polymers 0.000 description 2
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 2
- 229920001282 polysaccharide Polymers 0.000 description 2
- 239000005017 polysaccharide Substances 0.000 description 2
- 229920000053 polysorbate 80 Polymers 0.000 description 2
- 229930195734 saturated hydrocarbon Natural products 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 235000000346 sugar Nutrition 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 230000007704 transition Effects 0.000 description 2
- JVKUCNQGESRUCL-UHFFFAOYSA-N 2-Hydroxyethyl 12-hydroxyoctadecanoate Chemical compound CCCCCCC(O)CCCCCCCCCCC(=O)OCCO JVKUCNQGESRUCL-UHFFFAOYSA-N 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 229920002101 Chitin Polymers 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- OTMSDBZUPAUEDD-UHFFFAOYSA-N Ethane Chemical compound CC OTMSDBZUPAUEDD-UHFFFAOYSA-N 0.000 description 1
- SHBUUTHKGIVMJT-UHFFFAOYSA-N Hydroxystearate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OO SHBUUTHKGIVMJT-UHFFFAOYSA-N 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 229910025794 LaB6 Inorganic materials 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 229920001304 Solutol HS 15 Polymers 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- QYZIDAZFCCVJNS-UHFFFAOYSA-M [6-(dimethylamino)thioxanthen-3-ylidene]-dimethylazanium;chloride Chemical compound [Cl-].C1=CC(=[N+](C)C)C=C2SC3=CC(N(C)C)=CC=C3C=C21 QYZIDAZFCCVJNS-UHFFFAOYSA-M 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 239000007900 aqueous suspension Substances 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 238000003491 array Methods 0.000 description 1
- 239000012888 bovine serum Substances 0.000 description 1
- 229940098773 bovine serum albumin Drugs 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 239000003575 carbonaceous material Substances 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 230000003833 cell viability Effects 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 239000013065 commercial product Substances 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 239000002872 contrast media Substances 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 229920001577 copolymer Polymers 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- 239000007771 core particle Substances 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000001687 destabilization Effects 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 238000012377 drug delivery Methods 0.000 description 1
- 238000002296 dynamic light scattering Methods 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 238000001493 electron microscopy Methods 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 238000005189 flocculation Methods 0.000 description 1
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 1
- 238000001506 fluorescence spectroscopy Methods 0.000 description 1
- 239000007850 fluorescent dye Substances 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 230000005484 gravity Effects 0.000 description 1
- CPBQJMYROZQQJC-UHFFFAOYSA-N helium neon Chemical compound [He].[Ne] CPBQJMYROZQQJC-UHFFFAOYSA-N 0.000 description 1
- 229920001519 homopolymer Polymers 0.000 description 1
- 229940072106 hydroxystearate Drugs 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 239000008206 lipophilic material Substances 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 230000004807 localization Effects 0.000 description 1
- 229920002521 macromolecule Polymers 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 239000003094 microcapsule Substances 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 239000007764 o/w emulsion Substances 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 230000004962 physiological condition Effects 0.000 description 1
- 239000013612 plasmid Substances 0.000 description 1
- 229920005594 polymer fiber Polymers 0.000 description 1
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 1
- 229940068968 polysorbate 80 Drugs 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 239000010420 shell particle Substances 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 238000007447 staining method Methods 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 239000012498 ultrapure water Substances 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5107—Excipients; Inactive ingredients
- A61K9/513—Organic macromolecular compounds; Dendrimers
- A61K9/5146—Organic macromolecular compounds; Dendrimers obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyamines, polyanhydrides
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23P—SHAPING OR WORKING OF FOODSTUFFS, NOT FULLY COVERED BY A SINGLE OTHER SUBCLASS
- A23P10/00—Shaping or working of foodstuffs characterised by the products
- A23P10/30—Encapsulation of particles, e.g. foodstuff additives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23P—SHAPING OR WORKING OF FOODSTUFFS, NOT FULLY COVERED BY A SINGLE OTHER SUBCLASS
- A23P10/00—Shaping or working of foodstuffs characterised by the products
- A23P10/30—Encapsulation of particles, e.g. foodstuff additives
- A23P10/35—Encapsulation of particles, e.g. foodstuff additives with oils, lipids, monoglycerides or diglycerides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
- A61K8/11—Encapsulated compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
- A61K8/84—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds obtained by reactions otherwise than those involving only carbon-carbon unsaturated bonds
- A61K8/87—Polyurethanes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
- A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J13/00—Colloid chemistry, e.g. the production of colloidal materials or their solutions, not otherwise provided for; Making microcapsules or microballoons
- B01J13/02—Making microcapsules or microballoons
- B01J13/06—Making microcapsules or microballoons by phase separation
- B01J13/14—Polymerisation; cross-linking
- B01J13/16—Interfacial polymerisation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
- A61K2800/41—Particular ingredients further characterized by their size
- A61K2800/412—Microsized, i.e. having sizes between 0.1 and 100 microns
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
- A61K2800/41—Particular ingredients further characterized by their size
- A61K2800/413—Nanosized, i.e. having sizes below 100 nm
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Polymers & Plastics (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Dispersion Chemistry (AREA)
- Birds (AREA)
- Biophysics (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Food Science & Technology (AREA)
- Optics & Photonics (AREA)
- Physics & Mathematics (AREA)
- Nanotechnology (AREA)
- Biomedical Technology (AREA)
- Dermatology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Manufacturing Of Micro-Capsules (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Colloid Chemistry (AREA)
- Compositions Of Macromolecular Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP07291109.2 | 2007-09-18 | ||
| EP07291109A EP2039352A1 (en) | 2007-09-18 | 2007-09-18 | Aqueous-core lipid nanocapsules for encapsulating hydrophilic and/or lipophilic molecules |
| PCT/EP2008/062435 WO2009037310A2 (en) | 2007-09-18 | 2008-09-18 | Aqueous-core lipid nanocapsules for encapsulating hydrophilic and/or lipophilic molecules |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014143421A Division JP2014221802A (ja) | 2007-09-18 | 2014-07-11 | 親水性及び/又は親油性分子をカプセル化するための、水性コア脂質ナノカプセル |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2010539221A JP2010539221A (ja) | 2010-12-16 |
| JP2010539221A5 JP2010539221A5 (enExample) | 2011-10-27 |
| JP5989964B2 true JP5989964B2 (ja) | 2016-09-07 |
Family
ID=38785137
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010525348A Expired - Fee Related JP5989964B2 (ja) | 2007-09-18 | 2008-09-18 | 親水性及び/又は親油性分子をカプセル化するための、水性コア脂質ナノカプセル |
| JP2014143421A Pending JP2014221802A (ja) | 2007-09-18 | 2014-07-11 | 親水性及び/又は親油性分子をカプセル化するための、水性コア脂質ナノカプセル |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014143421A Pending JP2014221802A (ja) | 2007-09-18 | 2014-07-11 | 親水性及び/又は親油性分子をカプセル化するための、水性コア脂質ナノカプセル |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US9522121B2 (enExample) |
| EP (2) | EP2039352A1 (enExample) |
| JP (2) | JP5989964B2 (enExample) |
| KR (1) | KR20100074196A (enExample) |
| CN (2) | CN103800304A (enExample) |
| CA (1) | CA2699802A1 (enExample) |
| WO (1) | WO2009037310A2 (enExample) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9393315B2 (en) | 2011-06-08 | 2016-07-19 | Nitto Denko Corporation | Compounds for targeting drug delivery and enhancing siRNA activity |
| FR2950253B1 (fr) * | 2009-09-24 | 2011-09-23 | Ethypharm Sa | Nanocapsules lipidiques, procede de preparation et utilisation comme medicament |
| JP4834775B2 (ja) | 2010-03-04 | 2011-12-14 | 株式会社 資生堂 | 日焼け止め用組成物 |
| US10196637B2 (en) | 2011-06-08 | 2019-02-05 | Nitto Denko Corporation | Retinoid-lipid drug carrier |
| CN102441355B (zh) * | 2011-08-29 | 2013-10-30 | 华南理工大学 | 一种嵌段离聚体水相自组装纳米胶囊及其制备方法 |
| US20130251855A1 (en) * | 2012-03-21 | 2013-09-26 | Pepsico, Inc. | Aqueous product comprising oil-containing microcapsules and method for the manufacture thereof |
| CN104302690B (zh) | 2012-06-25 | 2017-07-18 | Lg化学株式会社 | 用于制备聚亚烷基碳酸酯模塑产品的乳液组合物和使用所述乳液组合物制备的树脂模塑产品 |
| US9598377B2 (en) | 2013-03-12 | 2017-03-21 | Cephalon, Inc. | Nanoparticulate and macroparticulate formulations |
| JP6377913B2 (ja) * | 2013-04-16 | 2018-08-22 | 積水化学工業株式会社 | マイクロカプセルの製造方法及びマイクロカプセル |
| TWI482782B (zh) * | 2013-05-31 | 2015-05-01 | Univ Nat Chiao Tung | 架接抗體之雙乳化核殼奈米結構 |
| CN103271406B (zh) * | 2013-06-08 | 2014-07-16 | 吉林大学 | 一种复合型两亲性芯材微胶囊冲剂及其制备方法 |
| FR3008900B1 (fr) * | 2013-07-25 | 2018-03-30 | Centre Nat Rech Scient | Nanoparticules lipidiques multicompartimentees |
| GB2520371B (en) * | 2014-05-01 | 2016-09-14 | Frito Lay Trading Co Gmbh | Snack food seasoning |
| GB2520370B (en) | 2014-05-01 | 2016-09-14 | Frito Lay Trading Co Gmbh | Snack food seasoning |
| AU2015265874B2 (en) * | 2014-05-30 | 2020-05-14 | AbbVie Deutschland GmbH & Co. KG | Highly drug-loaded poly(alkyl 2-cyanoacrylate) nanocapsules |
| JP6572598B2 (ja) * | 2015-04-02 | 2019-09-11 | 日本製鉄株式会社 | ナノ粒子の粒径測定方法 |
| CA2979751C (en) * | 2015-04-09 | 2020-05-12 | Saudi Arabian Oil Company | Encapsulated nanocompositions for increasing hydrocarbon recovery |
| KR102692648B1 (ko) * | 2015-12-04 | 2024-08-06 | (주)아모레퍼시픽 | 변성 단백질 수상 분산입자를 포함하는 화장료 조성물 및 이의 제조방법 |
| CN106942771A (zh) * | 2017-04-06 | 2017-07-14 | 贝因美婴童食品股份有限公司 | 一种用于制备营养品的胶囊 |
| US12239981B2 (en) * | 2018-07-11 | 2025-03-04 | The University Of Hong Kong | Automatic microfluidic system for continuous and quantitive collection of droplets |
| FR3092833B1 (fr) * | 2019-02-18 | 2021-07-16 | Commissariat Energie Atomique | Procede de fabrication de nanoparticules hybrides metal/polymere a faible distribution de tailles par polymerisation en mini-emulsion |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9414318D0 (en) * | 1994-07-15 | 1994-09-07 | Dowelanco Ltd | Preparation of aqueous emulsions |
| FR2725369B1 (fr) * | 1994-10-07 | 1997-01-03 | Oreal | Composition cosmetique ou dermatologique constituee d'une emulsion huile dans eau a base de globules huileux pourvus d'un enrobage cristal liquide lamellaire |
| DE19630176C2 (de) * | 1996-07-26 | 2000-11-02 | Babor Gmbh & Co Dr | Kosmetische und pharmazeutische Mittel, gebildet durch eine nach dem Phaseninversionsverfahren erzeugte W/O/W-Emulsion |
| US6277413B1 (en) * | 1998-07-17 | 2001-08-21 | Skyepharma, Inc. | Biodegradable compositions for the controlled release of encapsulated substances |
| FR2805761B1 (fr) * | 2000-03-02 | 2002-08-30 | Mainelab | Nanocapsules lipidiques, procede de preparation et utilisation comme medicament |
| GB0009735D0 (en) * | 2000-04-19 | 2000-06-07 | Zeneca Ltd | Formulation |
| US20020155084A1 (en) * | 2000-06-02 | 2002-10-24 | The Regents Of The University Of The Michigan | Nanoemulsion formulations |
| AU2003220670A1 (en) * | 2002-04-05 | 2003-10-27 | University Of Florida | Oil-filled nanocapsules from microemulsions utilizing cross-linkable surfactants |
| WO2004026453A2 (en) * | 2002-09-06 | 2004-04-01 | Genteric, Inc. | Microcapsules and methods of use |
| JP2006528700A (ja) * | 2003-05-20 | 2006-12-21 | エリモス・ファーマスーティカルズ・エルエルシー | 肥満の治療のためのカテコールブタンの投与のための方法と組成物 |
| CN1460468A (zh) * | 2003-06-05 | 2003-12-10 | 浙江大学 | 改进的包埋蛋白类药物和疫苗的高分子微球的制备方法 |
| US7200994B2 (en) * | 2003-07-02 | 2007-04-10 | Tiax Llc | Free piston stirling engine control |
| CN100402109C (zh) * | 2003-08-01 | 2008-07-16 | 卡拉科科学公司 | 经颅电刺激设备和方法 |
| JP4747534B2 (ja) * | 2003-09-01 | 2011-08-17 | 大正製薬株式会社 | W/o/w型複合エマルション |
| DE10351644A1 (de) * | 2003-11-05 | 2005-06-09 | Bayer Technology Services Gmbh | Verfahren zur Herstellung von lagerstabilen multiplen Emulsionen |
| US20070154560A1 (en) * | 2003-12-24 | 2007-07-05 | Mg Pharmacy Inc. | Process for producing microsphere and apparatus for producing the same |
| JP2005263647A (ja) * | 2004-03-16 | 2005-09-29 | Konica Minolta Medical & Graphic Inc | エマルション粒子含有造影剤 |
| WO2005102507A1 (en) * | 2004-04-20 | 2005-11-03 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | A method for the preparation of nanoparticles from nanoemulsions |
| US8211415B2 (en) * | 2004-10-13 | 2012-07-03 | L'oreal | Easily removable waterproof cosmetic care and/or makeup composition comprising at least one latex or pseudolatex |
| US8029709B2 (en) * | 2004-10-29 | 2011-10-04 | The University Of Cincinnati | Liquid core capsules and methods of synthesis thereof through interfacial polymerization |
| RU2426440C2 (ru) * | 2005-11-22 | 2011-08-20 | Нестек С.А. | Эмульсия масло-в-воде и ее применение для придания функциональности |
| CA2639921C (en) * | 2006-01-23 | 2014-01-21 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Microspheres comprising nanocapsules containing a lipophilic drug |
| CN100999656A (zh) * | 2006-12-22 | 2007-07-18 | 华南理工大学 | 潜热型纳米流体传热工质及其制备方法 |
-
2007
- 2007-09-18 EP EP07291109A patent/EP2039352A1/en not_active Ceased
-
2008
- 2008-09-18 US US12/678,868 patent/US9522121B2/en not_active Expired - Fee Related
- 2008-09-18 JP JP2010525348A patent/JP5989964B2/ja not_active Expired - Fee Related
- 2008-09-18 KR KR1020107008347A patent/KR20100074196A/ko not_active Ceased
- 2008-09-18 CA CA2699802A patent/CA2699802A1/en not_active Abandoned
- 2008-09-18 EP EP08804375A patent/EP2187877A2/en not_active Withdrawn
- 2008-09-18 WO PCT/EP2008/062435 patent/WO2009037310A2/en not_active Ceased
- 2008-09-18 CN CN201410049011.9A patent/CN103800304A/zh active Pending
- 2008-09-18 CN CN200880114087.8A patent/CN101842088B/zh not_active Expired - Fee Related
-
2014
- 2014-07-11 JP JP2014143421A patent/JP2014221802A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CN101842088B (zh) | 2014-03-12 |
| CA2699802A1 (en) | 2009-03-26 |
| CN103800304A (zh) | 2014-05-21 |
| US20100297247A1 (en) | 2010-11-25 |
| EP2187877A2 (en) | 2010-05-26 |
| US9522121B2 (en) | 2016-12-20 |
| WO2009037310A3 (en) | 2010-02-18 |
| JP2010539221A (ja) | 2010-12-16 |
| KR20100074196A (ko) | 2010-07-01 |
| JP2014221802A (ja) | 2014-11-27 |
| CN101842088A (zh) | 2010-09-22 |
| WO2009037310A2 (en) | 2009-03-26 |
| EP2039352A1 (en) | 2009-03-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP5989964B2 (ja) | 親水性及び/又は親油性分子をカプセル化するための、水性コア脂質ナノカプセル | |
| Astete et al. | Synthesis and characterization of PLGA nanoparticles | |
| Machado et al. | Preparation of calcium alginate nanoparticles using water-in-oil (W/O) nanoemulsions | |
| Strobel et al. | In situ cross-linking of alginate during spray-drying to microencapsulate lipids in powder | |
| Wang et al. | Development of microcapsules using chitosan and alginate via W/O emulsion for the protection of hydrophilic compounds by comparing with hydrogel beads | |
| PL229276B1 (pl) | Nanokapsuła do przenoszenia związku lipofilowego i sposób jej wytwarzania | |
| JP2013530168A (ja) | 親水性活性物質のためのコロイド状ナノスケールキャリア及びその製造方法 | |
| CN103126985A (zh) | 双乳化核壳纳米结构及其制备方法 | |
| US20140120169A1 (en) | Device and method for encapsulation of hydrophilic materials | |
| KR20220111862A (ko) | 친수성 활성물질을 캡슐화할 수 있는 하이드로겔 마이크로캡슐 | |
| Kumar et al. | Biocompatible PLGA-oil hybrid nanoparticles for high loading and controlled delivery of resveratrol | |
| Bazylińska et al. | The effect of anionic dicephalic surfactants on fabrication of varied-core nanocarriers for sustained release of porphyrin photosensitizers | |
| KR100719194B1 (ko) | 나노캡슐 형태의 콜로이드 입자의 제조방법 | |
| Yadava et al. | Low temperature, easy scaling up method for development of smart nanostructure hybrid lipid capsules for drug delivery application | |
| Zhang et al. | Preparation and evaluation of microcapsules of sodium alginate based on microfluidic technology | |
| Mannai et al. | Encapsulation of sunflower and flaxseed oils using Opuntia (Cactaceae) mucilage as a core-shell material through coacervation methods: A study on formulation, characterization, and in vitro digestion | |
| Montasser et al. | The effect of monomers on the formulation of polymeric nanocapsules based on polyureas and polyamides | |
| Khoee et al. | Effect of O/S/W process parameters on 17β-EV loaded nanoparticles properties | |
| Altas et al. | Preparation and investigation of Janus structured micro/nano carriers: Release kinetics of multiple drugs | |
| Goel et al. | Polymersomes as Next Generation Nanocarriers for Drug Delivery: Recent Advances, Patents, Synthesis and Characterization | |
| Puertas et al. | Microencapsulation of Doxorubicin Using Chitosan | |
| Kapuścińska et al. | Nanocapsules as carriers of active substances | |
| PL245026B1 (pl) | Sposób wytwarzania nanonośników poli(D,L laktydowych) stabilizowanych surfaktyną oraz nanonośniki wytworzone tym sposobem | |
| Othman et al. | Formulation of paracetamol− loaded poly (ε− caprolactone) nanoparticles by anti-solvent displacement method using glass capillary microfluidics: Statistical optimization and characterization | |
| Brzozowska | On the Use of Complex Coacervates for Encapsulation |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20110907 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20110907 |
|
| A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20130530 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20130611 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20130910 |
|
| A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20130918 |
|
| A711 | Notification of change in applicant |
Free format text: JAPANESE INTERMEDIATE CODE: A711 Effective date: 20130924 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20130924 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20131211 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20140311 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20140711 |
|
| A911 | Transfer to examiner for re-examination before appeal (zenchi) |
Free format text: JAPANESE INTERMEDIATE CODE: A911 Effective date: 20140807 |
|
| A912 | Re-examination (zenchi) completed and case transferred to appeal board |
Free format text: JAPANESE INTERMEDIATE CODE: A912 Effective date: 20140829 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20151225 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20160229 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20160609 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20160812 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 5989964 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| LAPS | Cancellation because of no payment of annual fees |